ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

3:00PM-4:30PM: Abstract Number: 1750

Safety and Preliminary Efficacy of CD19 CAR-T Cell Treatment in Rheumatic Disease – Data from the First Part of the Phase I/II CASTLE Basket Study

Abstracts: SLE – Treatment I: Cellular Therapy

3:00PM-4:30PM: Abstract Number: 1726

Safety, Cancer Progression, and Autoimmune Disease Activity in Patients with Pre-Existing Autoimmune Disease Undergoing CD19 CAR T Cell Therapy for Lymphoma: A Retrospective Comparative Cohort Study

Abstracts: Immunological Complications of Medical Therapy

3:00PM-4:30PM: Abstract Number: 1709

Sex Differences in Serum Proteomic Profiles of Males and Females with Psoriatic Arthritis

Abstracts: SpA Including PsA – Basic Science

3:00PM-4:30PM: Abstract Number: 1703

Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure

Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation

3:00PM-4:30PM: Abstract Number: 1755

Single Cell TCR Sequencing Suggests Potential Limitations of TRBV9-depleting Therapies in Axial Spondyloarthritis

Abstracts: SpA Including PsA – Treatment I

3:00PM-4:30PM: Abstract Number: 1701

STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity

Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation

3:00PM-4:30PM: Abstract Number: 1752

T Cell-Engaging Bispecific Antibodies to Target Autoreactive 9G4 Idiotope B Cells in Systemic Lupus Erythematosus

Abstracts: SLE – Treatment I: Cellular Therapy

3:00PM-4:30PM: Abstract Number: 1712

Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment

Abstracts: SpA Including PsA – Basic Science

3:00PM-4:30PM: Abstract Number: 1707

TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease

Abstracts: SpA Including PsA – Basic Science

3:00PM-4:30PM: Abstract Number: 1708

Unveiling the Uterine-Joint Axis: Dysbiosis and Subclinical Uterine Inflammation in Female Axial Spondyloarthritis Pathogenesis

Abstracts: SpA Including PsA – Basic Science

3:00PM-4:30PM: Abstract Number: 1745

Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)

3:00PM-4:30PM: Abstract Number: 1743

What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)

3:00PM-4:30PM: Abstract Number: 1756

What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor

Abstracts: SpA Including PsA – Treatment I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].